Therapeutic Asset Ratings

461 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
pf-08046054 Non-Small Cell Lung Carcinoma	Pfizer	P3	B (56)
PREDNISONE TABLETS Hepatocellular Carcinoma	Pfizer	P3	B (56)
Talzenna Non-Small Cell Lung Carcinoma	Pfizer	P3	B (56)
Talzenna Urothelial Carcinoma	Pfizer	P3	B (56)
Danuglipron Obesity Disorder	Pfizer	P2	B (56)
Avelumab Neoplasm	Pfizer	P3	CCC (55)
Cetuximab Glioma	Pfizer	P2	CCC (55)
Hycamtin Rhabdomyosarcoma	Pfizer	P2	CCC (55)
Palbociclib Castration-Resistant Prostate Carcinoma	Pfizer	P2	CCC (55)
Palbociclib Head And Neck Cancer	Pfizer	P2	CCC (55)
Metformin Sickle Cell Disease	Pfizer	P1	CCC (55)
Ponsegromab Pancreatic Ductal Adenocarcinoma	Pfizer	P2/3	CCC (55)
GIROCTOCOGENE FITELPARVOVEC TRANSGENE INSERT Hemophilia A	Pfizer	P3	CCC (54)
PEGASPARGASE Non-Small Cell Lung Cancer	Pfizer	P3	CCC (54)
pf-07248144 Breast Cancer	Pfizer	P3	CCC (54)
pf-08634404 Colorectal Neoplasm	Pfizer	P3	CCC (54)
Binimetinib Glioma	Pfizer	P2	CCC (54)
pf-08634404 Small Cell Lung Carcinoma	Pfizer	P2/3	CCC (54)
Utomilumab Cancer	Pfizer	P3	CCC (53)
Utomilumab Urothelial Carcinoma	Pfizer	P3	CCC (53)
Atirmociclib Lung Adenocarcinoma	Pfizer	P2	CCC (53)
Atirmociclib Liposarcoma	Pfizer	P2	CCC (53)
Atirmociclib Castration-Resistant Prostate Carcinoma	Pfizer	P2	CCC (53)
Atirmociclib Non-Small Cell Lung Carcinoma	Pfizer	P2	CCC (53)
Calaspargase Pegol Carcinoma	Pfizer	P2	CCC (53)

Showing 151 to 175 of 461 assets